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Abstract: Studies in the field of Alzheimer’s disease (AD) have shown the emergence of biomarkers
in biologic fluids that hold great promise for the diagnosis of the disease. A diagnosis of AD at
a presymptomatic or early stage may be the key for a successful treatment, with clinical trials
currently investigating this. It is anticipated that preventative and therapeutic strategies may be
stage-dependent, which means that they have a better chance of success at a very early stage—before
critical neurons are lost. Several studies have been investigating the use of cerebrospinal fluid (CSF)
and blood as clinical samples for the detection of AD with a number of established core markers,
such as amyloid beta (Aβ), total tau (T-tau) and phosphorylated tau (P-tau), being at the center of
clinical research interest. The use of oral samples—including saliva and buccal mucosal cells—falls
under one of the least-investigated areas in AD diagnosis. Such samples have great potential to
provide a completely non-invasive alternative to current CSF and blood sampling procedures.
The present work is a thorough review of the results and analytical approaches, including proteomics,
metabolomics, spectroscopy and microbiome analyses that have been used for the study and detection
of AD using salivary samples and buccal cells. With a few exceptions, most of the studies utilizing oral
samples were performed in small cohorts, which in combination with the existence of contradictory
results render it difficult to come to a definitive conclusion on the value of oral markers. Proteins
such as Aβ, T-tau and P-tau, as well as small metabolites, were detected in saliva and have shown
some potential as future AD diagnostics. Future large-cohort studies and standardization of sample
preparation and (pre-)analytical factors are necessary to determine the use of these non-invasive
samples as a diagnostic tool for AD.
Keywords: Alzheimer’s disease; diagnostics; biomarkers; early detection; salivary markers;
buccal cells
1. Introduction
With a rapidly aging population across the world, Alzheimer’s disease (AD) is expected to affect
75 million people in 2030 with much of the increase happening in developing countries [1]. It is now
recognized that pathologic changes in the brain commence several years before any obvious symptoms
of memory loss [2,3] with amyloid beta (Aβ) pathology thought to be a key initial step, followed
by the development of neurofibrillary tau pathology [4]. Three different stages were suggested to
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characterize the disease: preclinical (or asymptomatic) AD, mild cognitive impairment (MCI) due to
AD and dementia due to AD [5]. An accurate premorbid diagnosis of the disease remains challenging
and is currently based upon clinical presentations, as well as other imaging and biofluid biomarkers [6].
Positron emission tomography (PET) scans can reveal Aβ or tau accumulation in the brain whereas
magnetic resonance imaging (MRI) can measure function and reveal brain atrophy [3]. Specific
cerebrospinal (CSF) biofluid constituents, such as amyloid beta 42 (Aβ42), which correlates with
extracellular senile plaques [7], total tau (T-tau), which reflects the intensity of neuronal damage [8]
and phosphorylated tau (P-tau), which correlates with tangle pathology [8], were shown to have
excellent diagnostic accuracy [9]. However, the relatively invasive nature of CSF collection limits its
widespread use in routine primary care practice as the procedure is only rarely performed by general
practitioners [10]. Moreover, a lumbar puncture can be unpleasant and generate patient anxiety and
therefore is not preferred as a routine test.
Emerging evidence over the last decade supports the use of blood-based biomarkers for
investigating AD [11–15]. Depending on its intended use, an effective biomarker can serve different
purposes and have different characteristics. For instance, an ideal diagnostic marker would allow
a highly accurate point-of-care in vivo test with high sensitivity and specificity, whereas a screening
marker would combine low cost and favor sensitivity over specificity with further, more specific,
follow-up tests needed. In contrast to CSF, blood sampling could provide an ideal cost-effective and
relatively minimally invasive alternative sample for testing and has shown much promise over time for
AD diagnosis, screening, prognosis and disease monitoring. The huge benefit of using blood samples
comes from their potential to reveal AD-related changes at a presymptomatic or early stage of the
disease [16,17]. With the emergence of promising drug candidates for the treatment of AD [18], it is
anticipated that an early diagnosis is likely to define the course of the disease as administration of a
candidate treatment is expected to be most effective if provided as early as possible [10,19–21] (i.e.,
before severe neuronal loss). Clinical trials assessing promising drug agents in individuals diagnosed
with mild cognitive impairment (MCI) or early stage AD are currently ongoing (BAN2401: [22] and
aducanumab: [23]).
Work in the area of dementia using CSF and blood samples is fairly advanced with many
studies demonstrating useful differences between healthy controls and AD patients [9,15,17,24,25].
An overview of fluid biomarkers that have been replicated by different studies are reported in
Table 1 [25].
A more recent and admittedly less explored, area of interest is the use of saliva and oral buccal
mucosal cells as a means of diagnosing, monitoring and potentially screening for AD. This field
has attracted more attention within the clinical and scientific community in recent years due to the
successful advent of minimally invasive blood diagnostics as well as accumulating evidence linking AD
with “oral-cavity arising” biomarkers. For instance, several studies have correlated AD development
with oral bacteria and chronic periodontal disease [26–28]. It was hypothesized that oral bacteria or
their released endotoxins, may access the brain and induce microglial activation, which is a well-known
AD marker resulting in increased levels of proinflammatory cytokines, capable of initiating neuronal
loss and neurodegeneration [29].
Overall, several studies have assessed non-invasive, oral-derived biomarkers towards AD
diagnosis and this review will focus on the use of saliva and oral mucosa derived buccal cells, the most
popular sources of oral samples [30]. Herein, we present an overview of the literature across the field,
including potential diagnostic markers, promising analytical approaches as well as challenges and
limitations during sample collection and processing.
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Table 1. Replicated biomarkers detected in biofluids (cerebrospinal fluid and blood plasma/serum) of Alzheimer’s disease patients. Adapted from Zetterberg,
2017 [25].
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2. Saliva
2.1. Saliva: General Considerations
Being one of the simplest and easily accessible non-invasive biofluids, saliva has drawn great
attention as an ideal candidate for disease detection. Traditionally, salivary markers have been
utilized in diagnostic and monitoring tests for periodontal and other oral diseases [31,32]. More
recent technological advances, leading to an advent of sensitive analytical approaches and sensors,
have created the attractive opportunity for the diagnosis of other systemic diseases using saliva,
introducing a field of “salivary diagnostics” [33,34]. Previous studies have demonstrated the promise
of salivary specimens in diagnosing tumors [35–37], viral infections [38], gastrointestinal diseases [39],
diabetes [40,41] and muscle/joint disorders [33]. Salivary biomarkers have also emerged as a means
of diagnosing neurodegenerative conditions such as AD [42], Parkinson’s disease [43] and multiple
sclerosis [44].
A number of different hypotheses have been suggested over the years to explain the origin of
salivary biomarkers indicative of AD. For instance, it has been proposed that biomarkers may be secreted
by nerves into salivary glands due to their close proximity to the central nervous system [42]; or that
salivary proteins originate after transport of molecules from blood to saliva through ultrafiltration
and passive diffusion or active transport [45]. It is accepted that potential biomarkers reflecting
brain pathology can be released at small concentrations in the blood after crossing the blood–brain
barrier [46], which in the case of neurodegenerative disease is disrupted, thus leading to increased
permeability [47]. Moreover, ~500 mL CSF is absorbed daily into the blood circulation, which makes
blood an information-rich sample [48]. More recent studies have identified oral bacteria, capable of
causing chronic inflammation, as potential culprits behind AD and this could be another plausible
reason for the detection of salivary changes in AD affected individuals [26,27,49].
In comparison to the more-widely used blood specimens, saliva has some unique advantages,
such as relative ease of collection (no experienced personnel is required creating the exciting possibility
for self-collected samples) and completely non-invasive and inexpensive sample collection (no
anticoagulants needed, relatively easier storage under the human tissue authority guidelines and
permissions). Some challenges that need to be addressed in the use of saliva include the decreased
concentration of analytes [50], which necessitates more sensitive analytical approaches, as well as the
inability of approximately 1/3 of participants to produce an adequate saliva sample [51].
2.2. Saliva: Studies on AD
We identified 20 studies that reported the use of saliva as the sample of choice to study AD
(Table 2). Considering the multifactorial nature of the disease itself, it is not surprising that different
research groups have focused on the study of different biomarkers, both in isolation and as a panel of
markers, as well as different experimental techniques. Overall, some biomarkers and experimental
approaches have been studied more extensively than others, however, results are, in some cases,
contradictory between the different studies. In this section, we will present an overview of the main
findings of these studies.
2.3. Amyloid Beta (Aβ42 and/or Aβ40)
Most the included salivary studies (7/20) focused on the detection of the amyloid beta 42 (Aβ42)
peptide, with a smaller number (2/20) also focusing on the Aβ40 peptide. All of the studies used an
enzyme-like immunosorbent assay (ELISA) as their main experimental approach to detect Aβ. Most
of the studies (5/7) demonstrated increased levels of Aβ42 in AD patients [52–56] while the others
(2/7) showed undetectable or unchanged Aβ42 levels [42,57]. With the exception of a relatively larger
study by Bermejo-Pareja et al. [55], including 70 AD patients and 56 healthy volunteers serving as
the study’s controls, the remaining studies reported results on much smaller cohorts ranging from
7–28 AD patients and 7–38 healthy controls.
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Table 2. Comprehensive table of our literature review. Potential biomarkers, type of non-invasive sample used (saliva or buccal cells), experimental techniques,
number of participants and the main findings for each separate study are all reported.
Type of
Sample
Potential
Biomarker
Experimental
Technique Cohort (n) Main Findings References
Saliva
Aβ42 Sandwich ELISA AD: 15Healthy controls: 7 Increased Sabbagh et al. [52]
Sandwich ELISA AD: 23Healthy controls: 31 Increased McGeer et al. [53]
Sandwich ELISA AD: 7Pre-AD: 3Healthy controls: 26 Increased Lee et al. [54]
Sandwich ELISA AD: 20Healthy controls: 20 Not detected Lau et al. [57]
Sandwich ELISA AD: 70Healthy controls: 56 Increased Bermejo-Pareja et al. [55]
Nanobead ELISA AD: 28Healthy controls: 17 Increased Kim et al. [56]
Luminex ELISA AD: 21Healthy controls: 38 Not detected Shi et al. [42]
Aβ40 Sandwich ELISA AD: 70Healthy controls: 56 No change Bermejo-Pareja et al. [55]
Nanobead ELISA AD: 28Healthy controls: 17 No change Kim et al. [56]
T-tau Sandwich ELISA AD: 20Healthy controls: 20 No change Lau et al. [57]
Luminex ELISA AD: 21Healthy controls: 38 No change Shi et al. [42]
SIMOA
AD: 53
MCI: 68
Healthy controls: 160
No change Ashton et al. [58]
P-tau Sandwich ELISA AD: 20Healthy controls: 20 No change Lau et al. [57]
Luminex ELISA AD: 21Healthy controls: 38 No change Shi et al. [42]
P-tau/T-tau Luminex ELISA AD: 21Healthy controls: 38 Increased Shi et al. [42]
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Table 2. Cont.
Type of
Sample
Potential
Biomarker
Experimental
Technique Cohort (n) Main Findings References
Western blot
AD: 87
MCI: 55
Healthy controls: 167
(used in two consequent studies)
Increased Pekeles et al. [59]
Lactoferrin Mass spectrometry and sandwichELISA
AD: 116
MCI: 59
Healthy controls: 131
(used in two studies: discovery and validation)
Decreased Carro et al. [60]
Acetylcholinesterase Ellman’s colorimetric method AD: 36Healthy controls: 11 Decreased Sayer et al. [61]
Ellman’s colorimetric method AD: 15Healthy controls: 13 No change Boston et al. [62]
Ellman’s colorimetric method AD: 15Healthy controls: 15 No change Bakhtiari et al. [63]
Oral Microbiome
(Porphyromonas
Gingivalis)
qPCR AD: 10 Detection of P. Gingivalis DNA in 10/10 salivasamples Dominy et al. [26]
Oral Microbiome 16S rRNA sequencing AD: 39Healthy controls: 39
Significantly lower richness and diversity of
microbiota detected in AD than healthy
controls. Relative abundance of Moraxella,
Leptotrichia and Sphaerochaeta in the saliva of
AD was greatly increased, whereas that of
Rothia was significantly reduced
Liu et al. [64]
Metabolites: trehalose EG-IDFET biosensor AD: 20Healthy controls: 20 Increased Lau et al. [57]
Metabolites: multiple
marker panel LC-MS
AD: 29
MCI: 35
Healthy controls: 45
(used in two studies: discovery and validation)
High diagnostic accuracies (sensitivity:
71–100% and specificity: 80–100%) Huan et al. [65]
Metabolites: multiple
marker panel FUPLC-MS
AD: 256
Healthy controls: 218
High diagnostic accuracies (sensitivity:
82–99% and specificity: 91–98%) Liang et al. [66]
Metabolites: multiple
marker panel NMR spectroscopy
AD: 9
MCI: 8
Healthy controls: 12
High diagnostic accuracies (sensitivity: 91%
and specificity: 84%) Yilmaz et al. [67]
Oxidative stress
markers (protein
carbonyl levels)
ELISA
AD: 15
MCI: 21
Healthy controls: 30
No change Su et al. [68]
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Table 2. Cont.
Type of
Sample
Potential
Biomarker
Experimental
Technique Cohort (n) Main Findings References
Salivary flow,
antioxidants and
oxidative damage
products
Total protein content, colorimetry,
fluorimetry
AD: 24
Healthy controls: 80
Decreased salivary flow; increased total
protein concentration; decreased antioxidant
properties; increased levels of oxidative
damage to DNA, protein and lipids
Choromanska et al. [69]
Buccal cells Cytological &cytometric analysis Microscopic analysis
AD: 29
Healthy controls: 30
No changes in the cytoplasmic and nuclear
volumes Ozlece et al. [70]
Imaging of telomeres 3D telomeric analysis AD: 41Healthy controls: 41
Significantly different 3D telomere profiles.
Increased telomere number and aggregation
and decrease in telomere length
differentiated from normal to severe AD
Mathur et al. [71]
Altered cytological
parameters Automated laser-scanning cytometry
AD: 13
MCI: 13
Healthy controls: 26
Increased DNA content. Increased abnormal
nuclear shape. Decreased neutral lipid
content in MCI
Francois et al. [72]
Multiparameter
analysis Automated laser-scanning cytometry
AD: 20
MCI: 20
Healthy controls: 20
No change in DNA content, aneuploidy,
neutral lipids, tau. Lower tau in basal and
karyolytic cells versus differentiated cells.
Increased Aβ
Francois et al. [73]
Buccal micronucleus
cytome markers Buccal cytome assay
AD: 54
Healthy controls: 26
Decreased frequencies of basal, condensed
chromatin and karyorrhectic cells Thomas et al. [74]
Incidence of
chromosome 17 & 21
aneuploidy
FISH & fluorescently labeled DNA
probes
AD: 54
Healthy controls: 56 Increased Thomas et al. [75]
Telomere length Real time PCR AD: 54Healthy controls: 56 Decreased Thomas et al. [76]
T-tau Western blotELISA
AD: 34
Healthy controls: 67
Increased. Correlated with observed increase
in CSF Hattori et al. [77]
DNA structure Super-resolution microscopy AD: 37Healthy controls: 37
Increase of the measured DNA-free/poor
spaces (i.e., increase in interchromatin
compartment)
Garcia et al. [78]
Abbreviations: AD: Alzheimer’s disease; Aβ: amyloid beta; CSF: cerebrospinal fluid; EG-ISFET: extended gate ion-sensitive field-effect transistor; ELISA: enzyme-linked immunosorbent
assay; FISH: fluorescent in situ hybridization; FUPLC-MS: faster ultra-performance liquid; chromatography-mass spectrometry; NMR: nuclear magnetic resonance; LC-MS: liquid
chromatography-mass spectrometry; MCI: mild cognitive impairment; qPCR; quantitative polymerase chain reaction; rRNA: ribosomal RNA; SIMOA: single molecule array.
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More specifically, Sabbagh et al. [52] recruited 15 AD patients (7 males, mean age: 77.8 years,
mean mini-mental state examination (MMSE) score 19.0) and 7 normal controls (2 males, mean age:
60.4 years, mean MMSE 29.0) and demonstrated significantly higher salivary Aβ42 in AD patients than
in controls (51.7 ± 1.6 pg/mL for AD and 21.1 ± 0.3 pg/mL for controls, p < 0.001). Participants were
enrolled as mild and moderate AD according to the AD criteria established by the National Institute on
Aging and the Alzheimer’s Association (NIA-AA) [79]. Inclusion criteria were MMSE scores of 10–26
and age ≥50 years. Healthy patients with normal cognitive functioning and no neurodegenerative
disease who were intact functionally, physically and socially and were ≥50 years served as the control
group for this study.
McGeer et al. [53] employed 23 AD individuals (8 males, mean age: 71.3 years) and 31 heathy
controls (25 low-risk controls: 17 male, mean age: 54.2 years; and 6 high-risk controls: 3 males, mean
age: 69.0 years). However, it was not clarified whether diagnosis of AD cases was based on clinical
criteria and/or established biomarkers. Based on their findings, low-risk healthy controls had Aβ42
levels of ~20 pg/mL while high-risk controls and AD patients had increased Aβ42 levels ranging from
40–85 pg/mL (Aβ42 levels: AD > high-risk controls > low-risk controls). The authors concluded that
such an approach would be useful in the identification of those at risk at an age well below the typical
age of AD onset, thus reducing the prevalence of AD.
Lee et al. [54] determined salivary Aβ42 levels after treating the sample with thioflavin S as an
anti-aggregation agent and sodium azide as an antibacterial agent. Utilizing a total of 10 AD/pre-AD
cases (7 AD and 3 pre-AD) (3 males, mean age; 70.1) and 27 controls (including 1 Parkinson’s disease
case) (18 males, mean age: 54.6), the authors demonstrated a twofold increase in Aβ42 concentration in
the AD group when compared to controls, supporting its use in the diagnosis and potentially screening
of AD. It was not clear in the study whether AD diagnosis was based on standard clinical criteria
and/or established biomarkers.
Lau et al. [57] attempted to quantify Aβ42 levels using ELISA in 20 AD (8 male, mean age: 72.5,
mean MMSE score 18.1) and 20 healthy control samples (9 males, mean age: 66.1, mean MMSE score
28.7), however this specific biomarker was not detected in the saliva. All participants underwent
a series of clinical and neuropsychological tests (MMSE and the Clinical dementia Rating-Sum of
Boxes (CDR-SOB)) and the control group consisted of volunteers ≥50 years of age without a history of
neurological, psychiatric or other medical diagnosis that could contribute to cognitive impairment or
dementia. The CDR-SOB rating was 6.2 for the AD group and 0.2 for the controls. The same study
attempted measurement of other biomarkers indicative of AD, such as tau, results which will be
provided in the relevant sub-sections below.
In a study by Bermejo-Pareja et al. [55], an increase was observed in the Aβ42 levels of mild
(7.67 pg/mL) and moderate AD (11.70 pg/mL), but interestingly not in severe AD (3.03 pg/mL) when
compared with healthy controls (2.89 pg/mL). The cohort consisted of 70 AD (29 mild AD, 24 moderate
AD and 17 severe AD) (21 males, mean age: 77.2, mean MMSE score 17) and 56 controls (17 males,
mean age: 74.4, mean MMSE score was not determined). All AD cases were diagnosed according to
the Diagnostic and statistical manual of mental disorders (DSM)-IV and NINCDS–ADRDA criteria
and diagnosis required evidence of cognitive decline as well as impairment in social or occupational
function. All participants had extensive biochemical measurements and neuroimaging tests (brain MRI
and/or CT scan). Classification of mild, moderate and sever AD was performed and the diagnosis of
vascular dementia was excluded in all cases, using DSM-III-R criteria. The control group was formed
of family members or caregivers of the AD patients after a clinical interview with a senior neurologist
that showed a completely normal cognitive and functional level. No formal neuropsychological
battery was performed in the control group. The association that was found between Aβ42 and AD
was independent of established risk factors, including age or apolipoprotein E (ApoE) genotype, but
was dependent on sex and functional capacity. This study also analyzed the Aβ40 levels which were
found unchanged between AD patients and healthy subjects. The Aβ42/Aβ40 ratio was higher, but
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not statistically significant in mild and moderate AD patients, whereas it was unchanged in severe
AD patients.
Kim et al. [56] reported a statistically significant increase in the salivary Aβ42 levels, however there
was no statistical significance in Aβ40. This study included 28 AD (mean MMSE: 17.3) and 17 healthy
control samples (mean MMSE: 25.5) and was capable of detecting Aβ peptides at concentrations as
low as ~20 pg/mL. AD diagnosis was performed according to the clinical mental examination and on
the basis of cognitive dysfunction, interference in daily life and intellectual decline. MMSE scoring
was used as an indication of the cognitive function of patients and facilitate diagnosis. The control
group was composed of volunteers with no family history of AD and a normal cognitive function and
intellectual ability.
Shi et al. [42] involved 21 AD patients (10 male, mean age: 68.8, mean MMSE score 19.2) and
38 healthy volunteers (19 males, mean age: 69, mean MMSE score 29.4) in their study of saliva, showing
that Aβ42 was not detectable using a sensitive ELISA approach. The authors also compared the salivary
tau levels between AD and controls (more details in the relevant sub-section). The clinical diagnosis
of probable AD was made using the National Institute of Neurological, Communicative Disorders
and Stroke–Alzheimer’s disease and Related Disorders Association (NINCDS–ADRDA) criteria while
all control subjects were community volunteers with a MMSE score ≥27, paragraph recall scores >6,
no history of neurological disease and no history or evidence of cognitive or functional decline.
2.4. Tau (T-tau and/or P-tau)
We identified four studies of salivary tau biomarkers, either in combination with other markers
or in isolation. None of these studies found statistically significant changes in the levels of total tau
(T-tau) or phosphorylated tau (P-tau) while two studies showed consistent findings with an increased
P-tau/T-tau ratio (i.e., the proportion of the phosphorylated isoform of tau).
The Lau et al. study [57], apart from Aβ42, also studied tau protein levels in 20 AD and 20 healthy
control and found no significant differences in T-tau or P-tau. Details on the diagnosis of AD cases were
provided in the previous section (Amyloid beta). A separate metabolite (the salivary sugar trehalose)
was found, however, to distinguish between the two groups in the same study (more details in the
‘Metabolites’ sub-section).
Shi et al. [42], studying 21 AD patients and 38 healthy volunteers, showed no significant change
in T-tau or P-tau between the cohorts whereas the ratio P-tau/T-tau was significantly increased in the
AD group. Details on the diagnosis of AD cases were provided in the previous section.
Ashton et al. [58] was the first large-cohort study of its kind to employ the ultrasensitive single
molecule array (SIMOA) to measure T-tau in saliva. The cohort consisted of 53 AD patients (23 males,
mean age: 81.4) 68 individuals with mild cognitive impairment (MCI) (33 males, mean age: 79.8) and
160 healthy controls (66 males, mean age: 78.0) and final results showed no statistically significant
differences across these diagnostic groups, confirming the preliminary findings of the other two studies.
The diagnosis of probable AD was made according to Diagnostic and Statistical Manual for Mental
Diagnosis, fourth edition and NINCDS–ADRDA criteria [80]. MCI was defined according to Petersen
criteria [81]. Standardized clinical assessment included the MMSE and for global levels of severity the
Clinical Dementia Rating. The AD and MCI groups also had MRI scans.
Pekeles et al. [59] utilized western blot analysis to quantify the P-tau/T-tau ratio of a total of 87 AD
patients, 55 MCI and 167 healthy controls. For technical reasons, the analysis was carried out in two
rounds, the first with 148 samples including 46 AD (24 males, mean age: 80.0), 55 MCI (23 males,
mean age: 78.0) and 47 control subjects (15 males, mean age: 73.0) and the second with a total of
189 samples including 41 AD (17 males, mean age: 80.0), 44 controls (14 males, mean age: 72.0),
16 frontotemporal dementia (FTD) (11 males, mean age: 71.5), 12 neurology (i.e., Individuals with
brain diseases such as stroke, epilepsy and multiple sclerosis, but normal cognitive function) (5 males,
mean age: 55.0) and 76 young normal subjects (31 males, mean age: 32.0). Probable AD diagnosis
was given according to the McKhann et al. criteria for dementia [79], including significant cognitive
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impairment and symptoms sufficient to interfere with work or daily activities, a gradual onset of
symptoms, with either deficits in learning and recall or language, visuospatial or executive problems
and absence of other neurological diseases causing the symptoms. Evidence of pathophysiological
processes, such as neurofibrillary tangles or amyloid plaques further increased the certainty of diagnosis.
Diagnosis of MCI was made if the subject displayed subjective memory complaints, had normal
activities of daily living and general cognitive function, and demonstrated objective evidence of mild
memory impairment on testing. Healthy controls were volunteers aged ≥60 years and screened
with the Montreal Cognitive Assessment (MoCA), which had to be ≥25. The authors demonstrated
a significant elevation of P-tau/T-tau ratio, however large variations in the AD salivary levels limits
the utility of the test as a clinical biomarker. Moreover, the observed elevation in saliva did not
correlate with CSF tau or with brain measures, such as hippocampal volume.
2.5. Lactoferrin
Other biomarkers, apart from Aβ and tau proteins, have also shown potential as diagnostic means
in saliva specimens. For instance, lactoferrin, an antimicrobial peptide with a known Aβ-binding
ability, was found to be significantly reduced in AD patients in comparison to healthy controls [60].
Carro et al. [60] measured the salivary lactoferrin concentration in two separate studies, one being
the discovery and the other being the validation study. The discovery study utilized an initial mass
spectrometry approach and consisted of 80 AD individuals (31 males, mean age: 76.2), 44 MCI
(19 males, mean age: 75.2), 91 healthy controls (32 males, mean age: 73.7) and 69 Parkinson’s disease
patients, while the validation study utilized an ELISA assay and consisted of 36 AD patients (12 males,
mean age: 80.7), 15 MCI (10 males, mean age: 68.3) and 40 healthy controls (15 males, mean age: 66.8).
AD diagnosis was established according to the NINCDS–ADRDA guidelines [79] while MCI according
to the Petersen criteria [81]. Inclusion criteria for cognitively normal older individuals were MMSE
scores of 29.0, no history or clinical signs of neurological or psychiatric disease or cognitive symptoms.
Lactoferrin was positively correlated with MMSE score and Aβ42 while negatively correlated with
T-tau. It was also demonstrated that 14 out of 18 controls that were found with abnormally reduced
lactoferrin levels (<7.43 µg/mL) had converted to a clinical diagnosis of MCI or AD over the course of
the study (1–5 years), whereas that was not the case for subjects with normal/high levels of lactoferrin
(≥7.43 µg/mL). The authors concluded that this marker may prove promising in population screening
and in identifying underdiagnosed individuals with very early stages of MCI and AD.
2.6. Acetylcholinesterase Activity
Three separate studies were identified to measure acetylcholinesterase activity in saliva using
the Ellman colorimetric method [61–63]. Acetylcholinesterase (AchE) is an enzyme that degrades the
neurotransmitter acetylcholine (Ach) and therefore limits its postsynaptic effects. Acetylcholinesterase
inhibitors (AchE-I) are the primary drug prescribed in AD patients for symptom management, which
encourages an increase in and prolonged activity period for the released Ach due to the inhibition of
AchE. It was previously established that AD is linked with a deficiency in the brain neurotransmitter
ACh due to cholinergic neuron degradation. These same neurons synthesize and release the ACh
limiting AchE and thus levels of AChE are indicative of cholinergic neuron health. Several studies
have attempted to measure its activity in saliva.
Sayer et al. [61] recruited a total of 36 AD patients (22 AD responders to AchE-I (7 males, men age:
75.0) and 14 AD nonresponders (4 males, mean age: 75.0)) and 11 healthy controls (6 males, mean
age: 71.0). Subjects were diagnosed using McKhann et al. criteria [79], supplemented by information
from an informed caregiver and MMSE scores. Control subjects were relatives, caregivers or friends of
patients attending the clinic. None of the control subjects had evidence of any psychiatric syndrome
and all controls made no errors on the MMSE. This study reported a decreased activity of salivary
AchE in people with AD when compared to age-matched controls. In addition, a significant age-related
decrease was found in the catalytical activity of the enzyme in a control cohort, which reflected the
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age-association in cholinergic function. In addition, AchE was significantly decreased in the AchE-I
nonresponder group when compared to the responder group.
A later study by Boston et al. [62], with 15 AD patients (5 males, mean age: 83.5, mean MMSE score
20.4), 13 healthy controls (7 males, mean age: 80.8, mean MMSE score 29.1) and 13 vascular dementia
patients (9 males, mean age: 81.8, mean MMSE score 18.4), found a decreasing trend in the activity of
AChE within the AD cohort, however the differences were not statistically significant. Diagnosis of
AD was given according to NINCDS–ADRDA criteria while control subjects were individuals without
dementia or significant physical illness, mainly from the relatives of the patients who entered the study.
Bakhtiari et al. [63] employed 15 AD (9 males, mean age: 78.4) and 15 healthy controls (7 males,
mean age: 71.0) and showed that although there was a decreased AChE activity in AD, there was no
statistically significant difference (p value = 0.25). AD patients were previously diagnosed and were on
memantine therapy while the control group consisted of randomly selected elderly non-demented
subjects without neurological or cognitive disease.
The authors of the 2 later studies [62,63] demonstrating no change in the AChE activity
hypothesized that the observed decrease in the Sayer study [61] may be due to the treatment
with AChE-I that created long term adaptive changes in the production of AchE.
2.7. Oral Microbiome
More recent studies have focused on the oral microbiome as a diagnostic means for AD [26,64],
however these have included a smaller number of participants and therefore larger studies are required
to replicate these initial promising findings.
As part of a larger study using mainly brain tissue samples, Dominy et al. [26] also used a limited
number of matching CSF and saliva specimens in a pilot study of 10 probable AD patients with mild to
moderate cognitive impairment (MMSE: 15–20, mean age: 59.6). These subjects met the criteria of
MMSE scoring. Using a quantitative polymerase chain reaction (qPRC) assay, the authors quantified
the load Porphyromonas gingivalis (P. gingivalis), a keystone pathogen for the development of chronic
periodontitis which was considered as a high-risk factor for AD and found that 7/10 CSF and all
salivary samples were positive for the presence of P. gingivalis. According to the authors’ results, such
a test for P. gingivalis may serve as a differential diagnostic marker.
Liu et al. [64] analyzed salivary samples from 39 AD (18 males, mean age: 64.3) and 39 healthy
controls (21 males, mean age: 63.9). The diagnoses of probable or possible AD according to the
NINCDS–ADRDA criteria [82]. Neuropsychological assessment was performed on all patients,
including MMSE, neuropsychiatric inventory questionnaire (NPI), clinical dementia rating scale (CDR)
and activity of daily living scale (ADL). MMSE was also conducted with healthy controls. Using 16S
ribosomal RNA (rRNA) sequencing, they demonstrated significantly lower richness and diversity of
microbiota in AD patients. Relative abundance of specific bacteria, such as Moraxella, Leptotrichia and
Sphaerochaeta, was greatly increased whereas abundance of Rothia was significantly reduced. This study
provided further support for the role of oral microbiome in AD and reported the altered composition
of salivary microbiome, which may play role in the diagnosis of the disease.
2.8. Metabolites
Numerous studies have employed mass spectrometry techniques to develop a panel of
distinguishing metabolites [65–67] or even specific biosensor assays [57] to detect individual diagnostic
AD metabolites in saliva.
In the study of Lau et al. [57], which also studied the salivary levels of Aβ42, T-tau and P-tau with
ELISA, a more specific biosensor, namely extended gate ion-sensitive field-effect transistor (EG-ISFET),
was also used to study trehalose, a sugar molecule associated with the pathophysiology of AD.
Trehalose levels were increased in AD patients (n = 18) in comparison to healthy controls (n = 18),
leading the authors to conclude that such this test may serve as an alternative diagnostic tool for AD.
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Huan et al. [65] used a liquid chromatography–mass spectrometry (LC-MS) technique to investigate
potential metabolites that could serve as diagnostic AD biomarkers in saliva. The total sample number
(n = 109) was divided into a discovery phase study (n = 82) and a validation phase study (n = 27).
The discovery phase study included 22 AD (6 males, mean age: 77.1), 25 MCI (10 males, mean age:
70.4) and 35 healthy controls (13 males, mean age: 69.9), whereas the validation phase study included
7 AD (2 males, mean age: 70.1), 10 MCI (5 males, mean age: 71.5) and 10 controls (5 males, mean
age: 71.4). Patients were required to have a diagnosis of AD based on DSM-IV criteria for dementia
of the Alzheimer Type. Clinical assessments were performed as part of routine clinical evaluation,
which included caregiver report of cognitive decline and impaired functional status, mental status
evaluation of the patient (including the MMSE and Montreal Cognitive Assessment) and a physical
and neurological examination. All patients had a medication review and had routine laboratory
assessment for causes of dementia, including blood work and brain imaging according to Canadian
Consensus Guidelines. For the MCI and control groups, an extensive and fully objective (non-clinical)
classification was performed. After determining the top discriminating biomarkers, multi-metabolite
panels distinguished AD from controls and MCI individuals with high diagnostic accuracies, achieving
sensitivity ranging from 71–100% and a specificity of 80–100%. Saliva was characterized as a promising
biofluid for both unbiased and targeted AD biomarker discovery.
Liang et al. [66] also used metabolomics to detect salivary biomarkers for early diagnosis
of AD. This was one of the largest cohort studies with 256 AD samples (124 males, mean age:
78.6) and 218 age-matched healthy controls (102 males, mean age: 77.9). Diagnosis of AD
was based on the NINCDS–ADRDA criteria whereas controls did not have any neurologic or
cognitive disease. A number of different metabolites (sphinganine-1-phosphate, ornithine, phenyllactic
acid, inosine, 3-dehydrocarnitine and hypoxanthine) were studied as discriminatory for AD with
sphinganine-1-phosphate being able to achieve 99% sensitivity and 98% specificity.
Yilmaz et al. [67] used proton nuclear magnetic resonance (NMR) spectroscopy to study 9 AD
(3 males, mean age: 85.0), 8 MCI (3 males, mean age: 83.0) and 12 healthy controls (4 males, mean age:
82.0). Similar to other metabolomics studies a panel of biomarkers was utilized to distinguish between
the different cohorts with 91% sensitivity and 84% specificity.
2.9. Oxidative Stress Markers
Oxidative stress has been documented in tissues and biofluids of AD and MCI individuals. Su
et al. [68] quantified protein carbonyl levels, a marker of oxidative stress, by ELISA in saliva samples
of AD patients and found no significant difference between AD (n = 15) (10 males, mean age: 82.4) and
MCI (n = 21) (10 males, mean age: 81.1) from controls (n = 30) (13 males, mean age: 69.2), however they
reported a diurnal alteration in carbonyl levels. All AD subjects met the NINCDS–ADRDA criteria
for probable AD. MCI individuals exhibited cognitive decline (usually memory) of at least 6 months
duration that did not meet dementia criteria and scores of 0.5 on the Clinical dementia Rating scale.
All subjects had the MMSE test. Controls had no memory complaints and scored ≥ on the MMSE.
Choromanska et al. [69] studied 80 individuals with different subtypes of dementia (24 AD
(10 males, mean age: 77.9, mean MMSE score 13.1), 30 vascular dementia, 26 mixed dementia) and
80 healthy controls (25 males, mean age 80.1, mean MMSE score 27.4). The criteria for inclusion in
the study group covered: cognitive impairment with undisturbed consciousness seen in the clinical
picture and confirmed by the MMSE indicating a moderate dementia (score between 11 and 18 points
on a 30-point scale), at least 6 months of positive history of cognitive impairment and no history
of psychoactive substance abuse. Moreover, head CT scans of the patients excluded other diseases.
The control group included people with MMSE >23 and normal results of complete blood count and
biochemical blood tests. It was shown that in dementia patients the concentration of major salivary
antioxidants changes and the level of oxidative damage to DNA, proteins and lipids is increased
compared to healthy controls. Non-stimulated and stimulated salivary secretions were shown to
be significantly reduced in dementia patients. The study’s overall conclusion was that dementia
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was associated with disturbed salivary redox homeostasis and impaired secretory function of the
salivary glands.
3. Buccal Cells
3.1. Buccal Cells: General Considerations
Oral mucosa cytology samples can provide an almost non-invasive and relatively inexpensive
alternative for AD diagnosis. Numerous studies have focused on the study of buccal cells as biomarkers
in different neurological disorders since these cells (similarly to skin and brain cells) are derived
from ectodermal tissue [30] and therefore are thought to be embryologically related to the central
nervous system and share common AD-specific characteristics [83]. We would expect buccal cells
to be advantageous in comparison to saliva specimens due to the increased cellular content [30].
Nevertheless, only a few studies were identified in the literature to study oral mucosal epithelial cells
for AD diagnosis; herein, we present 9 of these studies (Table 2).
3.2. Buccal Cells: Specific Studies on AD
A study by Ozlece et al. [70] utilized microscopic analysis of oral mucosa to perform cytological
and cytometric analysis. The included cohort consisted of 29 AD patients (16 males, mean age: 78.9),
30 patients with Parkinson’s disease and 30 healthy individuals (15 males, mean age: 79.5). AD
diagnosis was given according to the NINCDS–ADRDA criteria. The MMSE and Clinical dementia
Scale were used to assess AD patients. The authors evaluated the nuclear and cytoplasmic volumes of
buccal cells derived from the different groups and did not find significant differences.
Mathur et al. [71] utilized three-dimensional imaging of telomeres to differentiate 41 AD patients
(19 males, mean age: 75.8) from 41 healthy volunteers (19 males, mean age: 74.3). The NINCDS–ADRDA
criteria were used for AD diagnosis. AD patients were categorized in mild, moderate or severe AD
based on their regular clinic visits and their scores on the MoCA and the MMSE. The control group
consisted of age- and gender-matched cognitively normal caregivers. All AD patients, from mild
to severe cases, had significantly different telomere profiles. An increase in telomer number and
aggregation as well as a decrease in the telomere length were shown to differentiate the different stages
of the disease (from normal to severe AD).
Two different studies by Francois et al. [72,73] utilized automated laser-scanning cytometry as
the experimental approach to analyze buccal cells and identify altered parameters in AD patients.
The earlier study [72] recruited 13 AD (2 males, mean age: 77.7), 13 MCI (2 males, mean age: 75.3)
and 26 healthy (4 males, mean age: 76.1) controls and showed increased DNA content and increased
abnormal shape in MCI and AD when compared to controls, as well as a decrease of neural lipid content
in MCI. Diagnosis of both MCI and AD was according to the criteria outlined by the NINCDS–ADRDA
while controls were not clinically diagnosed with MCI or AD. The subsequent study by the same
group [73] attempted to simultaneously measure cell types, nuclear DNA content and aneuploidy,
neutral lipid content, putative Tau and Aβ in buccal cells, some of which showed some contradictory
results with their earlier study. In this latter study, 20 AD, 20 MCI and 20 healthy controls were
included, with results showing no change in the DNA content, aneuploidy, neutral lipids and Tau,
whereas a significant decrease in Tau in basal and karyolytic cells when compared to differentiated
buccal cells. Aβ was found significantly higher in the AD group when compared to controls.
Thomas et al. conducted numerous studies towards the development of AD biomarkers [74–76].
A buccal cytome assay was used in one of these studies [74] to measure ratios of buccal cell populations
and micronuclei in 54 AD patients (16 males, mean age: 76.9) compared to 26 age- and gender-matched
controls (11 males, mean age: 68.7). Diagnosis was based on the NINCDS–ADRDA criteria. Frequencies
of basal cells (p < 0.0001), condensed chromatin cells (p < 0.0001) and karyorrhectic cells (p < 0.0001) were
found to be significantly lower in AD. The study’s authors concluded that buccal cytome biomarkers
may be associated with AD, but also urged for larger studies to replicate these pilot results. A second
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study from the same group [75], measured the incidence of chromosome 17 and 21 aneuploidy, which
have been suggested to contribute to the etiology of AD. Including 54 AD patient and 56 healthy
controls, they reported a 1.5-fold increase in trisomy 21 and a 1.2-fold increase in trisomy 17 in buccal
cells derived from AD. However, when they compared aneuploidy rates in the nuclei of hippocampus
brain cells, they found no significant differences between the groups, leading to the suggestion that
aneuploidy events may be influenced by genetic factors that may predispose to AD, but they are
unlikely to be a primary cause of AD brain pathology. Another study from Thomas et al. [76] studied
telomere length, which has been associated with aging and degeneration, using a real-time PCR method
in 54 AD and 56 controls. They observed a significantly lower telomere length in white blood cells
and buccal cells in AD, however telomere length was significantly higher in hippocampus cells of AD,
suggesting important differences in telomere maintenance depending on the sample type.
Hattori et al. [77] used oral epithelial cells exfoliated from 34 AD (11 males, mean age: 74.8),
29 vascular dementia and 67 healthy controls (29 males, mean age: 57.2) as well as CSF samples.
All patients fit the diagnosis of probable AD based on the NINCDS–ADRDA criteria. The healthy
control group was age-matched and showed no neurological symptoms, signs or dementia. Using
western blot and ELISA they determined the Tau protein levels, which showed a significant positive
correlation with levels in the CSF. Patients with AD had significantly higher levels of Tau than the
patients with vascular dementia and the controls. AD patients with a younger age at onset showed a
higher level of Tau than patients with later age at onset.
Finally, Garcia et al. [78] used super-resolution microscopy to study the structure of DNA in buccal
cells. Quantitation of the super-resolution DNA structure in 37 AD patients and 37 controls, revealed
that the structure of individuals with AD significantly differed from controls with an overall increase
in the measured DNA-free/poor spaces, which represents a significant increase in the interchromatin
compartment. AD diagnosis was made according to NINCDS–ADRDA criteria and patients were
classed as mild, moderate or severe AD based on their regular visits and their scores on the MoCA and
the MMSE.
4. Conclusions
With a few exceptions, most studies utilizing oral samples, either saliva or buccal cells, for AD
diagnosis, screening or disease monitoring have been performed in small-numbered cohorts, which
can be explained by the fact that this is a new, underexplored field. Low-powered studies and the
emergence of contradictory results between different publications and research groups, render it
difficult to come to a definitive conclusion on whether salivary markers can accurately detect AD.
Currently statistically insignificant studies may reach statistical significance, and vice versa, in future
larger-cohort studies. It should also be emphasized that the various studies have utilized different
diagnostic criteria, based on clinical diagnosis alone or confirmation with molecular and imaging
biomarkers. The cohorts with a standard clinical diagnosis run the risk of including other subtypes of
dementia, which may confound the results.
This review has reported extensively on studies that have used different experimental approaches,
ranging from molecular assays to metabolomics and cytological assessment, as well as different
biomarkers, ranging from Aβ and tau proteins to oral microbiome, toward AD investigation. Studies
were included irrespective of their results, demonstrating promising or not-promising biomarkers and
their final outcomes were fully described. Both advantages and disadvantages of salivary specimens
were discussed.
Further large-cohort studies are necessary to determine the use of these non-invasive oral samples
as a research and/or clinical tool for AD. There is need for independent studies from different research
groups to validate results and allow standardization of saliva collection, processing and storage.
Taking into consideration the plethora of different markers that have been so far suggested as
promising screening/diagnostic markers for AD, it is obvious that there are many causes with one
endpoint. It is therefore expected that a multiple panel marker approach will reveal more information
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rather than individual biomolecules. Such an approach could be used as a “first-line” screening tool to
identify individuals who may need further referral for imaging or CSF testing.
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